WO2018178947A2 - Compounds and compositions for treating hematological disorders - Google Patents

Compounds and compositions for treating hematological disorders Download PDF

Info

Publication number
WO2018178947A2
WO2018178947A2 PCT/IB2018/052232 IB2018052232W WO2018178947A2 WO 2018178947 A2 WO2018178947 A2 WO 2018178947A2 IB 2018052232 W IB2018052232 W IB 2018052232W WO 2018178947 A2 WO2018178947 A2 WO 2018178947A2
Authority
WO
WIPO (PCT)
Prior art keywords
carboxamide
oxazole
indazol
methylpyridin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/052232
Other languages
English (en)
French (fr)
Inventor
Venkateshwar Rao Gummadi
Susanta Samajdar
Kavitha Nellore
Girish DAGINAKATTE
Wesley Roy BALASUBRAMANIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2019552983A priority Critical patent/JP7333136B2/ja
Priority to NZ757707A priority patent/NZ757707B2/en
Priority to FIEP18777745.3T priority patent/FI3600270T3/fi
Priority to DK18777745.3T priority patent/DK3600270T3/da
Priority to AU2018242623A priority patent/AU2018242623B2/en
Priority to IL316364A priority patent/IL316364A/en
Priority to HRP20230657TT priority patent/HRP20230657T8/hr
Priority to MX2019011158A priority patent/MX389825B/es
Priority to RS20230544A priority patent/RS64411B1/sr
Priority to PL18777745.3T priority patent/PL3600270T3/pl
Priority to CN201880022870.5A priority patent/CN110691589A/zh
Priority to US16/498,866 priority patent/US11419875B2/en
Priority to BR112019018991-2A priority patent/BR112019018991A2/pt
Priority to CN202510475412.9A priority patent/CN120267671A/zh
Priority to EP18777745.3A priority patent/EP3600270B1/en
Priority to IL305150A priority patent/IL305150B2/en
Priority to EA201992322A priority patent/EA201992322A3/ru
Priority to KR1020257014711A priority patent/KR20250065441A/ko
Priority to SG11201908171T priority patent/SG11201908171TA/en
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Priority to IL293783A priority patent/IL293783B2/en
Priority to KR1020197032104A priority patent/KR102633530B1/ko
Priority to SM20230236T priority patent/SMT202300236T1/it
Priority to LTEPPCT/IB2018/052232T priority patent/LT3600270T/lt
Priority to CA3056893A priority patent/CA3056893A1/en
Priority to ES18777745T priority patent/ES2950764T3/es
Priority to KR1020247003678A priority patent/KR20240019391A/ko
Priority to EP23173240.5A priority patent/EP4252853A3/en
Priority to SI201830946T priority patent/SI3600270T1/sl
Priority to IL269536A priority patent/IL269536B/en
Publication of WO2018178947A2 publication Critical patent/WO2018178947A2/en
Priority to PH12019502138A priority patent/PH12019502138A1/en
Anticipated expiration legal-status Critical
Priority to US17/853,299 priority patent/US20220339161A1/en
Priority to JP2023129903A priority patent/JP2023154005A/ja
Priority to AU2024203943A priority patent/AU2024203943A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • 'm' and 'n' are independently 1 or 2.
  • n 0, 1 or 2;
  • n at each occurrence, is 0, 1, or 2.
  • disclosed herein is a use of a compound disclosed herein or a pharmaceutically acceptable salt or a stereoisomer thereof for the treatment and prevention of AML.
  • FIG. 2A depicts the %inhibition of proliferation in MV4-11 cells by Compound A.
  • FIG. 2B depicts the %inhibition of proliferation in MV4-11 cells by Compound B.
  • heterocycloalkyl includes azetidinyl, pyrrolidinyl, morpholinyl and piperidinyl. All heterocycloalkyl are optionally substituted by one or more aforesaid groups.
  • Certain compounds of the invention can form pharmaceutically acceptable salts with various organic bases such as lysine, arginine, guanidine, diethanolamine or metformin.
  • Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc, salts.
  • the compounds of the present invention can also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the present invention also embraces isotopically-labeled variants of the present invention which are identical to those recited herein, but for the fact that one or more atoms of the compound are replaced by an atom having the atomic mass or mass number different from the predominant atomic mass or mass number usually found in nature for the atom. All isotopes of any particular atom or element as specified are contemplated within the scope of the compounds of the invention, and their uses.
  • Exemplary isotopes that can be incorporated in to compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2 H ("D"), 3 H, n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 32 P, 33 P, 35 S, 18 F, 36 C1, 123 I and 125 I.
  • Isotopically labeled compounds of the present inventions can generally be prepared by following procedures well known in the art, such as by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • prevent refers to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease.
  • prevent also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.
  • the additional therapeutic compound is administered within about 5 minutes to within about 168 hours prior to or after administration of the compound of formula I, the compound of formula II, or the compound of formula III.
  • a subject who receives such treatment can benefit from a combined effect of different therapeutic compounds.
  • the present methods include a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen, halogen, alkyl, alkoxy, - NR a Rb, hydroxyl or hydroxyalkyl; R a is hydrogen or alkyl; and Rb is hydrogen, alkyl, acyl, hydroxyalkyl or -S0 2 -alkyl.
  • the present methods include a compound of formula (I) selected from:
  • A is O or S
  • the present methods include a compound of formula (II), (IIA), (IIB), or (IIC) or a pharmaceutically acceptable salt thereof, wherein Y is O or CH 2 .
  • the present methods include a compound of formula (IIB) or a pharmaceutically acceptable salt thereof, wherein A is O or S; Y is -CH 2 - or O; Ri is pyridyl, pyrazolyl, pyrrolidinyl; each of which is optionally substituted with alkyl, hydroxyl, hydroxyalkyl or -NR a Rb; R a and Rb are independently hydrogen; R 2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or -NR a Rb; wherein the substituent is alkyl, amino, halo or hydroxyl; R a and Rb are independently hydrogen, alkyl, acyl or heterocyclyl.
  • A is O or S
  • Y is -CH 2 - or O
  • Ri is pyridyl, pyrazolyl, pyrrolidinyl; each of which is optionally substituted with alkyl, hydroxyl,
  • the present methods include a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein R 2 is optionally substituted alkyl, preferably, methyl.
  • the present methods include a pharmaceutical composition
  • a pharmaceutical composition comprising the compound as disclosed herein, optionally admixed with a pharmaceutically acceptable carrier or diluent.
  • Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular compound or combination of compounds employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound(s) being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • the compounds of the present invention may be administered in combination with one or more other drugs (1) to complement and/or enhance prevention and/or therapeutic efficacy of the preventive and/or therapeutic drug effect of the compound of the present invention, (2) to modulate pharmacodynamics, improve absorption improvement, or reduce dosage reduction of the preventive and/or therapeutic compound of the present invention, and/or (3) to reduce or ameliorate the side effects of the preventive and/or therapeutic compound of the present invention.
  • the phrase "conjoint administration” refers to any form of administration of two or more different therapeutic compounds such that the second compound is administered while the previously administered therapeutic compound is still effective in the body (e.g., the two compounds are simultaneously effective in the patient, which may include synergistic effects of the two compounds).
  • FLT-3 or the genes that regulate FLT-3 expression, which may influence the outcome of the disease. Indeed, the ability of many of the compounds disclosed herein to inhibit FLT-3 is believed to contribute to their particular efficacy against AML, which is known to be sensitive to FLT-3 inhibition. Some patients may develop resistance to treatment with a FLT-3 inhibitor due to mutations that arise in the FLT-3 gene. Such FLT-3 mutations include, but are not limited to, D835H, D835V, D835Y, K663Q, N841I, internal tandem duplication (ITD), ITD and D835V, and ITD and F691L. However, compounds as disclosed herein have demonstrated efficacy against AML that has developed resistance against treatment with FLT-3 inhibitors. Accordingly, in some embodiments, disclosed compounds are effective in treating AML that is resistant to a FLT-3 inhibitor, such as AML that is characterized by cells having one or more of these mutations.
  • MDS Myelodysplasia syndromes
  • immature blood cells in the bone marrow do not mature and become healthy blood cells.
  • Some types may develop into acute myeloid leukemia.
  • problems with blood cell formation result in some combination of low red blood cells, low platelets, and low white blood cells.
  • Some types have an increase in immature blood cells, called blasts, in the bone marrow or blood.
  • the types of MDS are based on specific changes in the blood cells and bone marrow.
  • Compound A was prepared to the 50x stock of test compound was added to the assay well, before a reaction mix containing the enzyme and substrate was added. The reaction was initiated by the addition of ATP at the selected concentration. There was no pre-incubation of the compound with the enzyme/substrate mix prior to ATP addition, a working stock of 50x final assay concentration in 100% DMSO.
  • IC50 determinations data were analyzed using XLFit version 5.3 (ID Business Solutions). Sigmoidal dose-response (variable slope) curves are fit based on the mean result for each test concentration using non-linear regression analysis. Where the top and/or bottom of the curve fall >10% out with 100 and 0, respectively, either or both of these limits may be constrained at 100 and 0, provided that the QC criterion on R2 is met. Table 1 provides ICso data on representative kinase inhibition by Compound A.
  • FIG. 1 shows the activity of Compound A against IRAKI, IRAK4 and numerous variants of FLT-3, indicating its potency as a dual IRAK/FLT-3 inhibitor. It is expected that structurally analogous compounds possess this dual activity to a similar extent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/IB2018/052232 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders Ceased WO2018178947A2 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
SG11201908171T SG11201908171TA (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
FIEP18777745.3T FI3600270T3 (fi) 2017-03-31 2018-03-30 Yhdisteitä ja koostumuksia hematologisten häiriöiden hoitoon
DK18777745.3T DK3600270T3 (da) 2017-03-31 2018-03-30 Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
AU2018242623A AU2018242623B2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
IL293783A IL293783B2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
HRP20230657TT HRP20230657T8 (hr) 2017-03-31 2018-03-30 Spojevi i pripravci za liječenje hematoloških poremećaja
MX2019011158A MX389825B (es) 2017-03-31 2018-03-30 Compuestos y composiciones para tratar trastornos hematologicos.
RS20230544A RS64411B1 (sr) 2017-03-31 2018-03-30 Jedinjenja i kompozicije za lečenje hematoloških poremećaja
PL18777745.3T PL3600270T3 (pl) 2017-03-31 2018-03-30 Związki i kompozycje do leczenia zaburzeń hematologicznych
CN201880022870.5A CN110691589A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物
US16/498,866 US11419875B2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
BR112019018991-2A BR112019018991A2 (pt) 2017-03-31 2018-03-30 compostos e composições para tratar distúrbios hematológicos
CN202510475412.9A CN120267671A (zh) 2017-03-31 2018-03-30 用于治疗血液病的化合物和组合物
EP18777745.3A EP3600270B1 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
IL305150A IL305150B2 (en) 2017-03-31 2018-03-30 Compounds and preparations for the treatment of hematological disorders
EA201992322A EA201992322A3 (ru) 2017-03-31 2018-03-30 Соединения и композиции для лечения гематологических расстройств
KR1020257014711A KR20250065441A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
JP2019552983A JP7333136B2 (ja) 2017-03-31 2018-03-30 血液疾患を処置するための化合物及び組成物
NZ757707A NZ757707B2 (en) 2018-03-30 Compounds and compositions for treating hematological disorders
IL316364A IL316364A (en) 2017-03-31 2018-03-30 Compounds and preparations for the treatment of hematological disorders
KR1020197032104A KR102633530B1 (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
SM20230236T SMT202300236T1 (it) 2017-03-31 2018-03-30 Composti e composizioni per il trattamento di disturbi ematologici
LTEPPCT/IB2018/052232T LT3600270T (lt) 2017-03-31 2018-03-30 Junginiai ir kompozicijos hematologiniams sutrikimams gydyti
CA3056893A CA3056893A1 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
ES18777745T ES2950764T3 (es) 2017-03-31 2018-03-30 Compuestos y composiciones para tratar trastornos hematológicos
KR1020247003678A KR20240019391A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
EP23173240.5A EP4252853A3 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
SI201830946T SI3600270T1 (sl) 2017-03-31 2018-03-30 Spojine in sestavki za zdravljenje hematoloških motenj
IL269536A IL269536B (en) 2017-03-31 2018-03-30 Compounds and preparations for the treatment of hematological disorders
PH12019502138A PH12019502138A1 (en) 2017-03-31 2019-09-18 Compounds and compositions for treating hematological disorders
US17/853,299 US20220339161A1 (en) 2017-03-31 2022-06-29 Compounds and compositions for treating hematological disorders
JP2023129903A JP2023154005A (ja) 2017-03-31 2023-08-09 血液疾患を処置するための化合物及び組成物
AU2024203943A AU2024203943A1 (en) 2017-03-31 2024-06-11 Compounds and compositions for treating hematological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741011785 2017-03-31
IN201741011785 2017-03-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/498,866 A-371-Of-International US11419875B2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders
US17/853,299 Continuation US20220339161A1 (en) 2017-03-31 2022-06-29 Compounds and compositions for treating hematological disorders

Publications (1)

Publication Number Publication Date
WO2018178947A2 true WO2018178947A2 (en) 2018-10-04

Family

ID=63677680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/052232 Ceased WO2018178947A2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders

Country Status (25)

Country Link
US (2) US11419875B2 (https=)
EP (2) EP3600270B1 (https=)
JP (2) JP7333136B2 (https=)
KR (3) KR102633530B1 (https=)
CN (2) CN110691589A (https=)
AU (2) AU2018242623B2 (https=)
BR (1) BR112019018991A2 (https=)
CA (1) CA3056893A1 (https=)
DK (1) DK3600270T3 (https=)
EA (1) EA201992322A3 (https=)
ES (1) ES2950764T3 (https=)
FI (1) FI3600270T3 (https=)
HR (1) HRP20230657T8 (https=)
HU (1) HUE062648T2 (https=)
IL (4) IL269536B (https=)
LT (1) LT3600270T (https=)
MX (2) MX389825B (https=)
PH (1) PH12019502138A1 (https=)
PL (1) PL3600270T3 (https=)
PT (1) PT3600270T (https=)
RS (1) RS64411B1 (https=)
SG (1) SG11201908171TA (https=)
SI (1) SI3600270T1 (https=)
SM (1) SMT202300236T1 (https=)
WO (1) WO2018178947A2 (https=)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
WO2021004533A1 (zh) * 2019-07-10 2021-01-14 南京明德新药研发有限公司 作为irak4和btk多靶点抑制剂的噁唑类化合物
CN112480101A (zh) * 2019-09-12 2021-03-12 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
WO2022031330A1 (en) * 2020-08-03 2022-02-10 Curis, Inc. Compositions and methods for treating diseases and disorders
US11419875B2 (en) 2017-03-31 2022-08-23 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
WO2022216379A1 (en) * 2021-04-08 2022-10-13 Curis, Inc. Combination therapies for the treatment of cancer
US11492365B2 (en) 2020-02-07 2022-11-08 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
WO2022267673A1 (zh) 2021-06-21 2022-12-29 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023036706A1 (en) 2021-09-07 2023-03-16 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
WO2023036707A1 (en) 2021-09-07 2023-03-16 Bayer Aktiengesellschaft Substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines, salts thereof and their use as herbicidally active substances
US11691987B2 (en) 2014-01-13 2023-07-04 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
EP4248212A4 (en) * 2020-11-18 2024-09-25 Curis, Inc. METHODS OF TREATMENT OF PULMONARY DISEASES AND DISORDERS
US12291529B2 (en) 2023-02-16 2025-05-06 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
US12595264B2 (en) 2020-09-10 2026-04-07 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
EP4522772A4 (en) * 2022-05-11 2026-04-22 Curis Inc TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7620711B2 (ja) * 2020-12-25 2025-01-23 メッドシャイン ディスカバリー インコーポレイテッド アミドオキサゾール系化合物
CN114773331A (zh) * 2021-01-22 2022-07-22 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
EP4434981A4 (en) 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5427798A (en) 1992-08-14 1995-06-27 Burroughs Wellcome Co. Controlled sustained release tablets containing bupropion
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5731000A (en) 1993-07-30 1998-03-24 Glaxo Wellcome Inc. Stabilized pharmaceutical composition containing bupropion
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6583124B2 (en) 1997-07-29 2003-06-24 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050080056A1 (en) 1999-09-16 2005-04-14 Gerald Horn Ophthalmic formulations including selective alpha 1 antagonists
US20130035326A1 (en) 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US20150094315A1 (en) 2009-06-12 2015-04-02 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2015104688A1 (en) 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
WO2015193846A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
WO2017009806A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
DK1618092T3 (da) 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
WO2004103954A1 (ja) 2003-05-20 2004-12-02 Ajinomoto Co., Inc. アミド誘導体
JP2006526660A (ja) 2003-06-05 2006-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｖｒ１レセプターのモジュレーター
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
MXPA06012104A (es) 2004-04-22 2007-01-25 Bayer Cropscience Lp Metodo y composicion para controlar malas hierbas.
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
MX2007007226A (es) 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CN102633783A (zh) 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
KR20090049076A (ko) 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009013729A (es) * 2007-06-14 2010-01-25 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
EP2170834B1 (en) 2007-07-16 2014-01-08 AbbVie Inc. Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
MX2010001446A (es) 2007-08-08 2010-03-01 Merck Serono Sa Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple.
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ，インコーポレーテッド ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法
WO2010008847A2 (en) * 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
CN102281919A (zh) 2008-11-19 2011-12-14 先灵公司 二酰基甘油酰基转移酶的抑制剂
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
CN102264701A (zh) 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮脲
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
US20130053382A1 (en) 2010-04-30 2013-02-28 Sunil Paliwal Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
PT2585064T (pt) 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
KR20180099933A (ko) 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
CN106974913A (zh) 2011-04-12 2017-07-25 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
RS54936B1 (sr) * 2011-10-14 2016-11-30 Ambit Biosciences Corp Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6372666B2 (ja) 2012-11-03 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3102569A1 (en) 2014-02-06 2016-12-14 AbbVie Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
JP6994454B2 (ja) 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED
DK3600270T3 (da) 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
CA3079628A1 (en) 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5427798A (en) 1992-08-14 1995-06-27 Burroughs Wellcome Co. Controlled sustained release tablets containing bupropion
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5731000A (en) 1993-07-30 1998-03-24 Glaxo Wellcome Inc. Stabilized pharmaceutical composition containing bupropion
US5763493A (en) 1993-07-30 1998-06-09 Glaxo Wellcome Inc. Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US6583124B2 (en) 1997-07-29 2003-06-24 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US20050080056A1 (en) 1999-09-16 2005-04-14 Gerald Horn Ophthalmic formulations including selective alpha 1 antagonists
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20150094315A1 (en) 2009-06-12 2015-04-02 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US20130035326A1 (en) 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
WO2015104688A1 (en) 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2015193846A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
WO2017009806A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. NM 004119
ISSELBACHER ET AL.: "Harrison's Principles of Internal Medicine", vol. 13, 1996, pages: 1814 - 1882
MARTIN: "Remington's Pharmaceutical Sciences", 1975, MACK PUBL. CO.
NAGOYA, J. MED. SCI., vol. 77, 2015, pages 7 - 17
NAT. BIOTECHNOL., vol. 29, no. 11, 2011, pages 1046 - 51
NGUYEN, B. ET AL., ONCOTARGET, 2017, pages 1 - 14
RHYASEN, G. W. ET AL., BRITISH J. CANCER, 2014, pages 1 - 6
RHYASEN, G. W. ET AL., CANCER CELL, vol. 24, 2013, pages 90 - 104

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691987B2 (en) 2014-01-13 2023-07-04 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US12410193B2 (en) 2014-01-13 2025-09-09 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US11981685B2 (en) 2014-01-13 2024-05-14 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US11419875B2 (en) 2017-03-31 2022-08-23 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
JP2022540464A (ja) * 2019-07-10 2022-09-15 メッドシャイン ディスカバリー インコーポレイテッド Ｉｒａｋ４及びｂｔｋマルチターゲット阻害剤としてのオキサゾール化合物
CN114072401A (zh) * 2019-07-10 2022-02-18 南京明德新药研发有限公司 作为irak4和btk多靶点抑制剂的噁唑类化合物
CN114072401B (zh) * 2019-07-10 2023-11-21 南京明德新药研发有限公司 作为irak4和btk多靶点抑制剂的噁唑类化合物
JP7340680B2 (ja) 2019-07-10 2023-09-07 メッドシャイン ディスカバリー インコーポレイテッド Ｉｒａｋ４及びｂｔｋマルチターゲット阻害剤としてのオキサゾール化合物
WO2021004533A1 (zh) * 2019-07-10 2021-01-14 南京明德新药研发有限公司 作为irak4和btk多靶点抑制剂的噁唑类化合物
US12459940B2 (en) 2019-07-10 2025-11-04 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Oxazole compound as multi-targeted inhibitor of IRAK4 and BTK
WO2021047677A1 (zh) * 2019-09-12 2021-03-18 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
CN112480101A (zh) * 2019-09-12 2021-03-12 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
US11492365B2 (en) 2020-02-07 2022-11-08 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
US11926643B2 (en) 2020-02-07 2024-03-12 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
EP4188368A4 (en) * 2020-08-03 2024-09-04 Curis, Inc. Compositions and methods for treating diseases and disorders
WO2022031330A1 (en) * 2020-08-03 2022-02-10 Curis, Inc. Compositions and methods for treating diseases and disorders
US12595264B2 (en) 2020-09-10 2026-04-07 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
EP4248212A4 (en) * 2020-11-18 2024-09-25 Curis, Inc. METHODS OF TREATMENT OF PULMONARY DISEASES AND DISORDERS
US12178821B2 (en) * 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
US20220331330A1 (en) * 2021-04-08 2022-10-20 Curis, Inc. Combination therapies for the treatment of cancer
WO2022216379A1 (en) * 2021-04-08 2022-10-13 Curis, Inc. Combination therapies for the treatment of cancer
WO2022267673A1 (zh) 2021-06-21 2022-12-29 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023036707A1 (en) 2021-09-07 2023-03-16 Bayer Aktiengesellschaft Substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines, salts thereof and their use as herbicidally active substances
WO2023036706A1 (en) 2021-09-07 2023-03-16 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
EP4522772A4 (en) * 2022-05-11 2026-04-22 Curis Inc TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
US12291529B2 (en) 2023-02-16 2025-05-06 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists

Also Published As

Publication number Publication date
MX2022001343A (es) 2022-03-17
CN110691589A (zh) 2020-01-14
FI3600270T3 (fi) 2023-07-20
IL293783B2 (en) 2024-01-01
CN120267671A (zh) 2025-07-08
ES2950764T3 (es) 2023-10-13
EP3600270A4 (en) 2020-08-26
EP3600270A2 (en) 2020-02-05
HUE062648T2 (hu) 2023-11-28
EA201992322A2 (ru) 2020-07-31
DK3600270T3 (da) 2023-07-10
JP2023154005A (ja) 2023-10-18
IL305150A (en) 2023-10-01
KR20240019391A (ko) 2024-02-14
IL305150B2 (en) 2025-03-01
PT3600270T (pt) 2023-07-25
RS64411B1 (sr) 2023-09-29
IL269536B (en) 2022-07-01
IL293783B1 (en) 2023-09-01
IL316364A (en) 2024-12-01
NZ757707A (en) 2023-09-29
BR112019018991A2 (pt) 2020-04-14
MX389825B (es) 2025-03-20
AU2024203943A1 (en) 2024-07-04
EP3600270B1 (en) 2023-06-14
IL305150B1 (en) 2024-11-01
KR102633530B1 (ko) 2024-02-02
AU2018242623A1 (en) 2019-10-17
US20220339161A1 (en) 2022-10-27
AU2018242623B2 (en) 2024-05-02
HRP20230657T1 (hr) 2023-10-13
US20210290628A1 (en) 2021-09-23
EP4252853A2 (en) 2023-10-04
LT3600270T (lt) 2023-08-25
MX2019011158A (es) 2019-10-17
US11419875B2 (en) 2022-08-23
IL293783A (en) 2022-08-01
SMT202300236T1 (it) 2023-09-06
SI3600270T1 (sl) 2023-10-30
KR20250065441A (ko) 2025-05-12
PL3600270T3 (pl) 2023-09-25
CA3056893A1 (en) 2018-10-04
SG11201908171TA (en) 2019-10-30
PH12019502138A1 (en) 2020-06-29
EA201992322A3 (ru) 2020-09-30
EP4252853A3 (en) 2023-12-13
IL269536A (en) 2019-11-28
KR20190130023A (ko) 2019-11-20
JP2020512343A (ja) 2020-04-23
HRP20230657T8 (hr) 2023-11-10
JP7333136B2 (ja) 2023-08-24

Similar Documents

Publication Publication Date Title
US20220339161A1 (en) Compounds and compositions for treating hematological disorders
AU2023222890B2 (en) Compounds and compositions for treating hematological disorders
JP5707518B2 (ja) 置換型キノリン化合物及び使用方法
HK40013355A (en) Compounds and compositions for treating hematological disorders
NZ757707B2 (en) Compounds and compositions for treating hematological disorders
EA051654B1 (ru) Соединения и композиции для лечения гематологических нарушений
HK40031549A (en) Compounds and compositions for treating hematological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18777745

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3056893

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019018991

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019552983

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018242623

Country of ref document: AU

Date of ref document: 20180330

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197032104

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2018777745

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018777745

Country of ref document: EP

Effective date: 20191031

ENP Entry into the national phase

Ref document number: 112019018991

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190912

WWR Wipo information: refused in national office

Ref document number: 1020247003678

Country of ref document: KR